GLP-1 Medications and Fertility

Have you ever wondered whether GLP-1 medications, like semaglutide or tirzepatide, can affect your fertility?

These medications have become incredibly popular for managing type 2 diabetes and obesity. But beyond weight loss and blood sugar control, researchers are beginning to explore how they may influence reproductive health, ovulation, and even the chances of becoming pregnant.

And here’s something important: GLP-1 medications may affect fertility in more than one way. Some of those effects are indirect, meaning they happen because of changes in weight, insulin levels, and metabolic health. Others may involve the hormonal pathways that regulate reproduction and the environment in which eggs develop and embryos implant.

But there’s a major distinction we need to make right from the beginning: improved fertility does not necessarily mean these medications are safe to use during pregnancy. In fact, those are two very different questions.

So today, we’re breaking down how GLP-1 medications may influence fertility, why unexpected pregnancies can happen while taking them, what the research actually tells us, and what you should know if you’re planning to start a family.

What Are GLP-1 Medications?

Let’s start with the basics.

GLP-1 stands for glucagon-like peptide-1. It’s a hormone our intestines naturally release after we eat. It helps regulate blood sugar, signals fullness to the brain, and slows the movement of food out of the stomach.

Medications that mimic this hormone include semaglutide, sold under brand names such as Ozempic and Wegovy, and liraglutide, sold as Saxenda or Victoza. Tirzepatide, sold as Mounjaro or Zepbound, works on both GIP and GLP-1 receptors, so technically, it’s a dual-incretin medication rather than a selective GLP-1 receptor agonist.

These medications can improve blood sugar control, reduce appetite, and lead to substantial weight loss in many people.

And that’s where the fertility conversation begins.

How GLP-1 Medications May Indirectly Improve Fertility

Let’s talk about the indirect effects first, because this is where we have some of the most biologically plausible explanations for why fertility may improve in certain people.

First, weight loss.

We know that excess body weight can influence reproductive function, particularly when it contributes to hormonal imbalances and irregular ovulation.

Fat tissue is more than just a place where the body stores energy. It acts like an endocrine organ, releasing hormones and chemical messengers that influence metabolism and reproductive health. For example, fat tissue produces estrogen through an enzyme called aromatase and releases hormones such as leptin, which helps regulate appetite and energy balance. When excess fat accumulates, it can also contribute to chronic low-grade inflammation and metabolic dysfunction, which may interfere with normal reproductive hormone signaling.

When someone loses excess weight, some of these changes may improve, creating a more favorable environment for normal ovarian function. For people who previously experienced irregular periods or inconsistent ovulation, this may help their menstrual cycles become more regular and increase their opportunities to conceive.

However, weight loss does not improve fertility for everyone, and body weight alone does not determine whether someone can become pregnant. People in larger bodies can ovulate regularly and conceive, too.

Second, improving insulin resistance.

This is especially important for people with polycystic ovary syndrome, or PCOS, and those with type 2 diabetes.

Insulin is the hormone that helps move glucose from the bloodstream into cells for energy. When the body becomes resistant to insulin, cells don’t respond as effectively, so the pancreas produces more insulin to compensate. This can lead to elevated insulin levels and contribute to high blood sugar and type 2 diabetes.

In people with PCOS, elevated insulin levels can also stimulate the ovaries to produce more androgens, including testosterone. These higher androgen levels can interfere with normal follicle development, making it harder for an egg to mature and be released regularly. This can lead to irregular periods or anovulation, which means not ovulating at all.

GLP-1 medications can improve blood sugar control and insulin sensitivity, and the weight loss they promote can further support these improvements. In people with type 2 diabetes, this helps manage glucose levels and improve metabolic health. In people with PCOS, reducing excess insulin may also help lower androgen levels and support more regular ovulation.

So, while the mechanisms differ somewhat, improving metabolic health can benefit both blood sugar regulation and reproductive function. It’s important to remember, though, that GLP-1 medications are not established fertility treatments and are not approved specifically to induce ovulation.

Can GLP-1 medications directly affect fertility?

Now, beyond weight loss and improved insulin sensitivity, researchers are investigating whether GLP-1 medications may also influence the reproductive system more directly.

To understand how this might happen, let’s talk about the hypothalamic-pituitary-ovarian axis, or the HPO axis.

Think of the HPO axis as the communication network that coordinates the menstrual cycle. The hypothalamus in the brain releases a hormone called GnRH, which signals the pituitary gland to release follicle-stimulating hormone, or FSH, and luteinizing hormone, or LH. FSH helps ovarian follicles develop, while a surge in LH triggers ovulation, releasing a mature egg from the ovary. The ovaries also produce estrogen and progesterone, which regulate the menstrual cycle and help prepare the uterine lining for a potential pregnancy.

It’s a finely coordinated system, and metabolic signals can influence how it functions.

Research suggests that obesity and metabolic dysfunction can disrupt reproductive signaling through several pathways, including changes in sex hormone metabolism, chronic inflammation, and altered communication between the brain and ovaries. In PCOS, for example, changes in GnRH and LH signaling can contribute to excess androgen production and impaired follicle development.

GLP-1 receptors are found in several tissues involved in metabolism, and experimental research suggests that GLP-1 signaling may interact with pathways involved in reproductive hormone regulation. Researchers are exploring whether these medications could influence the HPO axis and ovarian function in ways that extend beyond weight loss alone.

However, we need to be careful about what we can conclude. Although some studies suggest GLP-1 signaling may affect reproductive pathways, direct effects on the human HPO axis have not been firmly established. Much of the evidence comes from animal studies and laboratory research, while human studies often cannot separate the potential direct effects of the medication from the effects of weight loss and improved metabolic health.

So, the possibility is intriguing, but we cannot yet say that GLP-1 medications directly normalize the HPO axis in humans.

Ultimately, the clearest potential fertility benefits currently relate to improvements in weight-related metabolic dysfunction and insulin resistance, particularly in people with PCOS. Whether GLP-1 medications also have meaningful direct effects on reproductive hormones and ovarian function remains an important question for future research

What about egg quality?

Another important question is whether these medications can influence the quality of the egg itself.

Egg development is a complex process that depends on cellular energy production, mitochondrial function, hormonal signaling, and the environment within the ovarian follicle.

Insulin resistance, oxidative stress, and chronic inflammation may negatively affect some of these processes. These factors have been associated with impaired reproductive function, although their effects vary among individuals.

By improving insulin sensitivity and reducing metabolic stress, GLP-1 medications could potentially help create a more favorable environment for ovarian function.

Researchers are also exploring whether GLP-1 signaling has direct effects on ovarian inflammation and cellular pathways involved in follicular development.

But here’s the key distinction: improved metabolic health does not automatically mean improved egg quality.

We don’t currently have enough high-quality human evidence to conclude that GLP-1 medications improve egg quality, increase the number of genetically normal eggs, or improve IVF success rates.

Those are important questions that future research needs to answer.

And what about the endometrium?

Let’s talk about the endometrium, which is the inner lining of the uterus.

For a pregnancy to become established, an embryo must implant into a receptive endometrium. This process depends on coordinated hormonal signaling, appropriate tissue development, and carefully regulated immune and inflammatory responses.

Metabolic dysfunction and insulin resistance have been associated with changes in endometrial function in some populations. Chronic inflammation may also affect the uterine environment.

Researchers are investigating whether the metabolic improvements associated with GLP-1 medications could help support a healthier endometrial environment.

There is also emerging experimental interest in GLP-1 signaling and its potential anti-inflammatory effects in reproductive tissues.

However, we need to separate what is biologically plausible from what has been demonstrated clinically. Direct anti-inflammatory benefits in the human endometrium, improved endometrial receptivity, and higher implantation rates have not been established as effects of GLP-1 medications.

In other words, the science is promising enough to investigate, but not strong enough to recommend these medications as treatments for egg quality, endometrial health, or infertility.

Why Are Unexpected Pregnancies Happening?

This brings me to my next point, unexpected pregnancies on GLP-1’s. They can happen because weight loss and improved insulin sensitivity may help restore ovulation, particularly in people with PCOS who previously ovulated irregularly.

There’s also an important medication interaction to be aware of. GLP-1 medications slow gastric emptying, but their effects on oral contraceptives vary. Semaglutide and liraglutide have not shown a clinically significant reduction in oral contraceptive exposure in studies. Tirzepatide is different: it can reduce oral contraceptive effectiveness, so the prescribing information recommends using a non-oral contraceptive or adding a barrier method, such as condoms, for four weeks after starting treatment and for four weeks after each dose increase.

Vomiting or severe diarrhea can also interfere with oral contraceptive absorption. So, if you’re taking a GLP-1 medication and relying on the pill, check with your healthcare provider about the precautions specific to your medication.

What Does the Research Say About GLP-1 Exposure During Pregnancy?

Lastly, let’s address one of the biggest questions: what happens if someone becomes pregnant while taking a GLP-1 medication?

First, these medications are not recommended during pregnancy because there isn’t enough human evidence to establish their safety.

Animal studies have raised concerns about reproductive toxicity, including fetal growth effects and skeletal abnormalities with certain medications. The findings vary by GLP-1 and study, and some effects occurred alongside maternal weight loss or reduced food intake. Nevertheless, these findings are one reason clinicians recommend avoiding these medications during pregnancy.

But what about human data?

One clinical study worth discussing is a prospective, multicenter observational cohort study.

Researchers examined 168 pregnancies involving exposure to GLP-1 receptor agonists during the first trimester. They compared these pregnancies with two groups: women with diabetes who used other diabetes medications and women who were overweight or had obesity.

The researchers did not identify an increased risk of major birth defects or pregnancy loss associated with GLP-1 exposure in the comparisons they studied.

That is reassuring information, especially for people who discover a pregnancy after they’ve already been taking one of these medications.

However, we need to interpret those results carefully.

The study was relatively small, and the confidence intervals were wide. It cannot rule out uncommon risks, identify every possible medication-specific effect, or establish that these drugs are safe throughout pregnancy.

So, the takeaway here is that the available human evidence offers some reassurance following inadvertent early exposure, while larger studies are still needed.

If you discover that you’re pregnant while taking one of these medications, don’t panic. Early exposure does not automatically mean that harm has occurred.

But you should stop the medication and contact your obstetrician or other prescribing clinician promptly to discuss the exposure and your next steps.

And, If you’re taking a GLP-1 to manage diabetes, it’s particularly important to arrange an alternative treatment plan during pregnancy, because uncontrolled blood sugar can also pose risks.

What If You’re Planning to Get Pregnant?

Let’s say you’re taking a GLP-1 medication for weight management or type 2 diabetes and you’re thinking about starting a family.

What should you do?

The first step is to talk with your prescribing clinician and obstetrician or fertility specialist before you begin trying to conceive.

The recommended time to discontinue a GLP-1 medication depends on the specific GLP-1.

For semaglutide, the prescribing information recommends stopping at least two months before a planned pregnancy because the medication takes a relatively long time to clear from the body.

For tirzepatide or any other GLP-1, the appropriate timing should be discussed with your clinician using the current product information and your individual circumstances. 

You should also have a plan for maintaining your metabolic health after stopping treatment. Some people regain weight after discontinuation, and blood sugar may rise in people taking these medications for diabetes.

Your clinician can help you develop a nutrition, activity, and medication plan that supports your health before and during pregnancy.

And, if pregnancy occurs while you’re taking one, stop the medication and contact your OB/GYN or prescribing clinician.

As we wrap up today’s conversation, one thing is clear: the connection between GLP-1 medications and fertility is an exciting and evolving area of research. There’s so much potential to explore, and we’re only beginning to understand what it could mean for reproductive health. At the same time, more research is needed to fully understand the benefits, risks, and implications for those trying to conceive. The good news? Science is continuing to move forward, and every new study brings us one step closer to better answers. So, stay curious, stay informed, and as always, partner with your healthcare provider to make decisions that are right for you. 

Thanks again for listening to The Peptide Podcast. 

If you’d like to support what we do, check out our Partners Page—you’ll find the link at the top of the show notes. You’ll find some amazing products that we personally use and trust. And, every order placed through these links helps keep the podcast going!

Until next time, be well, and have a happy, healthy week.